Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Notes underwriting agrmnt
Inv. presentation
PRECIGEN, INC. (XON) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025",
"Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval"
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2023 8-K Quarterly results
Docs: "Precigen Reports First Quarter 2023 Financial Results and Business Updates"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates"
01/27/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PRECIGEN, INC. 42,857,143 Shares of Common Stock Underwriting Agreement",
"Company”), in connection with its registration statement on Form S-3, as amended , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended relating to the proposed public offering of up to 49,285,714 shares of the common stock, no par value per share, of the Company , all of which shares are to be sold by the Company pursuant to the Underwriting Agreement dated January 24, 2023 between the Company and J.P. Morgan Securities LLC as Representative of the several Underwriters named in Schedule 1 thereto , as described in the prospectus, dated July 2, 2020, that forms part of the Registration Statement , as supplemented by the Prospectus Supplement, dated January 24, 2023 (together with the Registration Statement Prospectus, the “Prospectus"
01/24/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse ™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis"
11/09/2022 8-K Quarterly results
09/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Precigen Names Rutul R. Shah Chief Operating Officer"
08/22/2022 8-K Quarterly results
08/09/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement",
"Exhibits 5.1 and 23.1 Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www.hoganlovells.com August 9, 2022 Board of Directors Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, MD 20876 To the addressee referred to above: We are acting as counsel to Precigen, Inc., a Virginia corporation , in connection with its registration statement on Form S-3, as amended , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended , relating to the issuance and sale of up to $100,000,000 of shares of common stock, no par value, of the Company from time to time and at various prices in an “at the market offering” pursuant to the terms of the Controlled Equity Offering SM Sales Agreement, d..."
08/08/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/04/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precigen Achieves Significant Clinical Progress for UltraCAR-T and AdenoVerse ™ Therapies"
10/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer"
08/09/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/26/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Hogan Lovells US LLP",
"Underwriting Agreement, between Precigen, Inc. and the Underwriters named therein"
01/13/2021 8-K Quarterly results
12/02/2020 8-K Unregistered Sales of Equity Securities  Interactive Data
11/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results"
10/09/2020 8-K Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits  Interac...
Docs: "Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note"
09/25/2020 8-K Quarterly results
09/25/2020 8-K Quarterly results
08/14/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy